Avidity Biosciences Surge on Acquisition Deal Catalyst
about 2 months ago
Nathan Hager
"And one stock in particular is soaring on some deal news. Yeah, that's Avidity Biosciences up 44% in pre-market trade. Novartis has agreed to buy the Biioarma company for $72 a share. So, we are rising 44% up just shy to $71 a share. It was a $12 billion deal for Novartis, the largest acquisition for the Swiss pharma giant in over a decade, and it seeks to boost its drug pipeline with this acquisition. Evidity has experimental drugs focused on rare earth diseases."
Avidity Biosciences is experiencing a significant pre-market surge of 44% as Novartis moves to acquire the company at $72 per share. This acquisition is a strategic move for Novartis to enhance its drug pipeline, positioning Avidity as a high-impact play in biotech.
Scores
Alpha Potential
9.0/10
Novelty
8.0/10
Credibility
8.0/10
Timeliness
9.0/10
Overall
8.4/10
Sentiment
Bullish
Conviction
High
Tier
Trade Call
Related Stocks
Episode Information
Episode:
Nvidia Outperforms; Avidity Biosciences Rallies; Carter's Falls | Stock Movers
Source:
Stock Movers
Published:
October 27, 2025
Idea Type:
Stock Idea